ArticleQuantitative imaging in medicine and surgery2025
Kupffer phase echo level ratio in contrast-enhanced ultrasound for differentiating malignant liver tumors.
Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Primary hepatic diffuse large B-cell lymphoma in a patient with polycystic liver disease: a case report and literature review.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Kupffer phase contrast-enhanced ultrasound (CEUS) using Sonazoid allows real-time assessment of Kupffer cell function, which is often disrupted in malignant liver tumors. While qualitative assessment is established, quantitative studies remain limited. This study aimed to evaluate the diagnostic value of the echo level ratio (ELR) derived from the Kupffer phase for differentiating hepatocellular carcinoma (HCC) from non-HCC liver malignancies. Methods: This retrospective study included 221 patients with pathologically confirmed malignant liver tumors who underwent CEUS between September 2023 and January 2025. CEUS was performed using Sonazoid with both vascular and Kupffer phase imaging. Time-intensity curve (TIC) analysis was used to derive vascular phase parameters [peak intensity (PI), time to peak (TTP), wash-in area under the curve (WiAUC), wash-out area under the curve (WoAUC), and wash-in and wash-out area under the curve (WiWoAUC)], and ELR was calculated as the mean intensity of the lesion divided by that of the adjacent liver parenchyma during the Kupffer phase. Diagnostic performance was assessed using receiver operating characteristic analysis. Inter- and intra-observer agreement was evaluated using intraclass correlation coefficients (ICCs). Results: Of the 221 included patients, 97 had HCC and 124 had non-HCC tumors (49 intrahepatic cholangiocarcinoma, 75 metastases). ELR was significantly lower in the HCC group than in the non-HCC group [1.20 (1.12, 1.26) Conclusions: Kupffer phase quantification using the ELR provides a reproducible parameter for distinguishing HCC from other malignant liver tumors. Although sensitivity is modest, ELR offers high specificity, and its combination with vascular phase CEUS parameters significantly improves overall diagnostic accuracy. This supports the integration of ELR into CEUS workflows for more confident noninvasive liver tumor characterization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.